Table 3.
Prognostic factors for 2-year GRFS after adult allogeneic HSCT.
| Factors | n | Events | % | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | ||||
| Age at HSCT | |||||||||
| ≤35 | 139 | 74 | 53.2 | 1.452 | 1.102–1.913 | 0.008 | 1.080 | 0.799–1.459 | 0.617 |
| >35 | 238 | 160 | 67.2 | ||||||
| EBMT risk score | |||||||||
| ≤2 | 155 | 73 | 47.1 | 2.165 | 1.640–2.857 | <0.001 | 1.835 | 1.354–2.486 | <0.001 |
| >2 | 222 | 161 | 72.7 | ||||||
| Gender | |||||||||
| Female | 168 | 89 | 53.0 | 1.456 | 1.118–1.896 | 0.005 | 1.348 | 1.032–1.761 | 0.028 |
| Male | 209 | 145 | 69.4 | ||||||
| Disease type | |||||||||
| Nonmalignant | 48 | 16 | 33.3 | 2.495 | 1.500–4.149 | <0.001 | 1.979 | 1.178–3.324 | 0.010 |
| Malignant | 329 | 218 | 66.3 | ||||||
| Disease type | |||||||||
| Myeloid | 176 | 117 | 66.5 | 0.836 | 0.647–1.081 | 0.172 | |||
| Nonmyeloid | 201 | 117 | 58.2 | ||||||
| Conditioning | |||||||||
| Nonmyeloablative | 129 | 75 | 58.1 | 1.135 | 0.863–1.494 | 0.365 | |||
| Myeloablative | 248 | 159 | 64.1 | ||||||
| Conditioning | |||||||||
| Others | 252 | 150 | 59.5 | 1.246 | 0.953–1.627 | 0.107 | |||
| 12 Gy TBI based | 125 | 84 | 67.2 | ||||||
| Conditioning | |||||||||
| Others | 303 | 179 | 59.1 | 1.494 | 1.104–2.022 | 0.009 | 1.115 | 0.811–1.532 | 0.503 |
| Fludarabine based | 74 | 55 | 74.3 | ||||||
| Donor type | |||||||||
| Matched sibling | 181 | 119 | 65.7 | 0.976 | 0.755–1.261 | 0.851 | |||
| Others | 196 | 115 | 58.7 | ||||||
| Type 2 DM | |||||||||
| No | 362 | 224 | 61.9 | 1.260 | 0.699–2.375 | 0.474 | |||
| Yes | 15 | 10 | 66.7 | ||||||
| Smoking history | |||||||||
| No | 353 | 216 | 61.2 | 1.415 | 0.903–2.364 | 0.122 | |||
| Yes | 24 | 18 | 75.0 | ||||||
| Posttransplant CMV reactivation | |||||||||
| No | 187 | 107 | 57.2 | 1.349 | 1.042–1.746 | 0.023 | 1.170 | 0.899–1.523 | 0.242 |
| Yes | 190 | 127 | 66.8 | ||||||
| PTLD | |||||||||
| No | 362 | 228 | 62.9 | 1.463 | 0.651–3.292 | 0.357 | |||
| Yes | 15 | 6 | 40.0 | ||||||
CI: confidence interval; HR: hazard ratio; EBMT: European Group for Blood and Marrow Transplantation; HSCT: hematopoietic stem cell transplantation; PTLD: posttransplant lymphoproliferative disorders; DM: diabetes mellitus; CMV: cytomegalovirus; TBI: total body irradiation.
Factors with statistical significance (p < 0.05) upon univariate analysis were included in multivariate analysis.